Unknown

Dataset Information

0

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.


ABSTRACT: In acute myeloid leukemia (AML), chemotherapy resistance remains prevalent and poorly understood. Using functional proteomics of patient AML specimens, we identified MEF2C S222 phosphorylation as a specific marker of primary chemoresistance. We found that Mef2cS222A/S222A knock-in mutant mice engineered to block MEF2C phosphorylation exhibited normal hematopoiesis, but were resistant to leukemogenesis induced by MLL-AF9 MEF2C phosphorylation was required for leukemia stem cell maintenance and induced by MARK kinases in cells. Treatment with the selective MARK/SIK inhibitor MRT199665 caused apoptosis and conferred chemosensitivity in MEF2C-activated human AML cell lines and primary patient specimens, but not those lacking MEF2C phosphorylation. These findings identify kinase-dependent dysregulation of transcription factor control as a determinant of therapy response in AML, with immediate potential for improved diagnosis and therapy for this disease.Significance: Functional proteomics identifies phosphorylation of MEF2C in the majority of primary chemotherapy-resistant AML. Kinase-dependent dysregulation of this transcription factor confers susceptibility to MARK/SIK kinase inhibition in preclinical models, substantiating its clinical investigation for improved diagnosis and therapy of AML. Cancer Discov; 8(4); 478-97. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 371.

SUBMITTER: Brown FC 

PROVIDER: S-EPMC5882571 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

Similar Datasets

2018-07-23 | GSE94453 | GEO
2018-07-23 | GSE107073 | GEO
2018-07-23 | GSE107072 | GEO
2018-07-23 | GSE107071 | GEO
| PRJNA418953 | ENA
| PRJNA418959 | ENA
| PRJNA418960 | ENA
| S-EPMC7404064 | biostudies-literature
| S-EPMC6687545 | biostudies-literature
| S-EPMC7427158 | biostudies-literature